<DOC>
	<DOCNO>NCT01664039</DOCNO>
	<brief_summary>The purpose study evaluate effect TRAVATAN® versus LUMIGAN® intraocular pressure ( IOP ) ocular surface inflammatory biomarkers .</brief_summary>
	<brief_title>An Efficacy Tolerability Study TRAVATAN® Versus LUMIGAN®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<criteria>Diagnosed either openangle glaucoma ocular hypertension least one eye treatment naïve glaucoma treatment . Intraocular pressure ( IOP ) 19 mmHg 35 mmHg least one eye , would study eye . IOP consider safe ( opinion investigator ) , eye , way assure clinical stability vision optic nerve throughout study period . Able follow instruction willing able attend study visit . Best correct Snellen visual acuity 6/60 ( 20/200 , 1.0 LogMAR ) good eye . Must read , sign , date Ethics Committeeapproved informed consent form . Other protocoldefined inclusion criterion may apply . Known medical history allergy , hypersensitivity poor tolerance component study medication use study deem clinically significant opinion Principal Investigator . Any abnormality prevent reliable applanation tonometry either eye . Concurrent infectious/noninfectious conjunctivitis , keratitis uveitis either eye . Prior treatment dry eye punctal plug , punctal cautery , Restasis® topical ocular corticosteroid . History ocular surface disease ( dry eye ) current/prior use dry eye medication ( either overthe counter prescription medication ) . Contact lens wear . Intraocular conventional surgery laser surgery either eye less three month prior Screening Visit . Use systemic medication know affect IOP ( e.g. , oral betaadrenergic blocker , alphaagonists blocker , angiotensin convert enzyme inhibitor calcium channel blocker ) , stable course least 7 day prior Screening Visit anticipated change dosage course study . Women childbearing potential use reliable mean birth control , pregnant , lactate . Unwilling risk possibility darken iris eyelash change . Participation investigational study within 30 day prior Screening Visit . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
</DOC>